Drug Trial Radar · NCT07761429
A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
402
Planned (sponsor's estimate)
Start
Jul 8, 2026
Primary completion
Dec 30, 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTDIndustry
- Sponsor type
- Industry
- First posted
- Aug 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of F520 combined with paclitaxel plus carboplatin as first-line treatment for cancer of unknown primary.This study consists of two parts, with a total planned enrollment of 402 patients.Primary Endpoint is Objective Response Rate (ORR) assessed by Independent Review Committee (IRC) based on RECIST 1.1 Secondary Endpoints included ORR、PFS、DOR;Incidence and severity of Adverse Events (AE), Serious Adverse Events (SAE), and abnormal laboratory parameters.
Conditions
- Cancer of Unknown Primary Site
Interventions
F520 combined with chemotherapyDrug
F520: 200 mg per dose, intravenous infusion, infusion time \>30 minutes, Q3W; maximum 2 years. Refer to drug preparation manual for details. Paclitaxel: 175 mg/m², intravenous infusion, infusion time \>3 hours, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details. Carboplatin: AUC 5, intravenous infusion, infusion time \>30 minutes, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details.
placebo combined with chemotherapyDrug
Placebo: 200 mg per dose, intravenous infusion, infusion time \>30 minutes, Q3W; maximum 2 years. Refer to drug preparation manual for details. Paclitaxel: 175 mg/m², intravenous infusion, infusion time \>3 hours, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details. Carboplatin: AUC 5, intravenous infusion, infusion time \>30 minutes, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS assessed by IRCTime frame: 2years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai tumor hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.